--- title: "Adjuvant Astrocytomas Grade 3 A072301 | Sutter Health" description: "Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas" url: "https://www.sutterhealth.org/research/clinical-trials/adjuvant-astrocytomas-grade-3-a072301-2082117649" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Adjuvant Astrocytomas Grade 3 A072301 # Adjuvant Astrocytomas Grade 3 A072301 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/adjuvant-astrocytomas-grade-3-a072301-2082117649#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07215910). #### Locations - Sutter Health System Wide #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas ![Christopher U Jones, M.D., FACR](https://dyn.mktgcdn.com/p/6fMCH4vO97TB6M5QvU1pl5Qui1fViPD5KLLubfev_dQ/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Christopher U Jones, M.D., FACR Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/christopher-u-jones-md-facr-1049681071) ## Email us to enroll - [Email Sutter Health System Wide](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Adjuvant%20Astrocytomas%20Grade%203%20A072301%20in%20Sutter%20Health%20System%20Wide&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Metastasis Brain NEO212-01](https://www.sutterhealth.org/research/clinical-trials/metastasis-brain-neo212-01-2079170524) An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors **Status:** Open to Enrollment - Clinical trial ### [Neoadjuvant Neuroblastoma ANBL2131](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-neuroblastoma-anbl2131-2022194957) A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma **Status:** Open to Enrollment - Clinical trial ### [Recurrent Glioblastoma SC9-GBM-03](https://www.sutterhealth.org/research/clinical-trials/recurrent-glioblastoma-sc9-gbm-03-2064304836) A Randomized, Open-label, Multicentric, Two-arm Pivotal Trial of SonoCloud-9 Combined With Carboplatin (CBDCA) vs Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma. **Status:** Closed to Enrollment - Clinical trial ### [Recurrent or Progressive IDH1 Mutated Glioma NEO100-01](https://www.sutterhealth.org/research/clinical-trials/recurrent-or-progressive-idh1-mutated-glioma-neo100-01-2066909715) An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation **Status:** Open to Enrollment - Clinical trial ### [Residual, Progressive or Recurrent Grade II or III Meningioma NEO100-02](https://www.sutterhealth.org/research/clinical-trials/residual-progressive-or-recurrent-grade-ii-or-iii-meningioma-neo100-02-2066911166) An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-astrocytomas-grade-3-a072301-2082117649#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Adjuvant Astrocytomas Grade 3 A072301"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-astrocytomas-grade-3-a072301-2082117649#medicalwebpage","name":"Adjuvant Astrocytomas Grade 3 A072301","description":"Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-astrocytomas-grade-3-a072301-2082117649","inLanguage":"en-US","dateModified":"2026-08-25","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-astrocytomas-grade-3-a072301-2082117649#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-astrocytomas-grade-3-a072301-2082117649#breadcrumblist"},"mentions":[{"@type":"Person","name":"Christopher U Jones, M.D., FACR","url":"https://www.sutterhealth.org/research/investigators/christopher-u-jones-md-facr-1049681071","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-astrocytomas-grade-3-a072301-2082117649#medicaltrial","name":"Adjuvant Astrocytomas Grade 3 A072301","alternateName":"Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-astrocytomas-grade-3-a072301-2082117649","description":"Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas","identifier":"NCT07215910","code":{"@type":"MedicalCode","codeValue":"NCT07215910","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT07215910","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Brain Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sutter Health System Wide"}]} ```